Success Metrics

Clinical Success Rate
93.8%

Based on 30 completed trials

Completion Rate
94%(30/32)
Active Trials
7(16%)
Results Posted
87%(26 trials)
Terminated
2(4%)

Phase Distribution

Ph early_phase_1
3
7%
Ph not_applicable
1
2%
Ph phase_3
4
9%
Ph phase_4
22
49%
Ph phase_1
7
16%
Ph phase_2
8
18%

Phase Distribution

10

Early Stage

8

Mid Stage

26

Late Stage

Phase Distribution45 total trials
Early Phase 1First-in-human
3(6.7%)
Phase 1Safety & dosage
7(15.6%)
Phase 2Efficacy & side effects
8(17.8%)
Phase 3Large-scale testing
4(8.9%)
Phase 4Post-market surveillance
22(48.9%)
N/ANon-phased studies
1(2.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.9%

30 of 33 finished

Non-Completion Rate

9.1%

3 ended early

Currently Active

7

trials recruiting

Total Trials

45

all time

Status Distribution
Active(9)
Completed(30)
Terminated(3)
Other(3)

Detailed Status

Completed30
Recruiting7
unknown3
Not yet recruiting2
Terminated2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
45
Active
7
Success Rate
93.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 13 (6.7%)
Phase 17 (15.6%)
Phase 28 (17.8%)
Phase 34 (8.9%)
Phase 422 (48.9%)
N/A1 (2.2%)

Trials by Status

withdrawn12%
completed3067%
unknown37%
not_yet_recruiting24%
recruiting716%
terminated24%

Recent Activity

7 active trials
Showing 5 of 45
completedphase_4

Efficacy of Suvorexant on Post-operative Sleep Disturbance

NCT05823844
not_yet_recruitingphase_4

Suvorexant 3 - PE-PC

NCT07686731
completedphase_4

Evaluation of Suvorexant for Reduction of Brain Reactivity in Patients With Cannabis Use Disorder (Pilot Study)

NCT06584942
recruitingphase_2

Suvorexant for Treatment of AUD and PTSD

NCT06679062
recruitingphase_1

Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms

NCT06484075
View all 45 trials

Clinical Trials (45)

Showing 20 of 45 trialsScroll for more
NCT05823844Phase 4

Efficacy of Suvorexant on Post-operative Sleep Disturbance

Completed
NCT07686731Phase 4

Suvorexant 3 - PE-PC

Not Yet Recruiting
NCT06584942Phase 4

Evaluation of Suvorexant for Reduction of Brain Reactivity in Patients With Cannabis Use Disorder (Pilot Study)

Completed
NCT06679062Phase 2

Suvorexant for Treatment of AUD and PTSD

Recruiting
NCT06484075Phase 1

Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms

Recruiting
NCT06326684Early Phase 1

Suvorexant and Alcohol

Recruiting
NCT06788522Phase 4

The Effects of Orexin Antagonism on Fear Extinction in PTSD

Not Yet Recruiting
NCT06655883Phase 3

A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)

Recruiting
NCT05593653Phase 4

Treating Insomnia and Improving Metabolic Health in Midlife Women With Insomnia

Completed
NCT05546554Phase 2

Trial of Suvorexant for Sleep in Children With Autism

Recruiting
NCT04287062Phase 2

Examining the Role of the Orexin System in Sleep and Stress in Persons With Opioid Use Disorder

Completed
NCT05656534Early Phase 1

Orexin Receptor Antagonists as Modulators of Threat Sensitivity in Individuals With Alcohol Use Disorder

Completed
NCT04014387Phase 4

Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)

Completed
NCT05145764Phase 2

Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl

Recruiting
NCT03642028Phase 4

Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress

Recruiting
NCT06834386Phase 4

Suvorexant for Insomnia to Prevent Delirium in Hospitalized Cancer Patients

Withdrawn
NCT05106153Phase 1

A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem

Completed
NCT03110315Phase 4

A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia

Completed
NCT04571944Phase 3

Efficacy and Safety of Suvorexant (MK-4305) for Reducing Incidence of Delirium in Japanese Participants at High Risk of Delirium (MK-4305-085)

Completed
NCT04262193Phase 2

Dual-Orexin Antagonism As a Mechanism for Improving Sleep and Drug Abstinence in Opioid Use Disorder

Terminated

Drug Details

Intervention Type
DRUG
Total Trials
45